Rx Promotion Remains Potential Political Liability, Attorneys Warn
Executive Summary
Pharmaceutical companies should prepare for increased Congressional scrutiny of promotional activities heading into the 2002 mid-term elections, attorney John Kamp (Wiley, Rein and Faulding, Washington, D.C.) told a Drug Information Association marketing workshop.
You may also be interested in...
Senate Transition Puts Kennedy Atop Health: Rx Marketing In Spotlight?
The return of Sen. Kennedy (D-Mass.) to the chairmanship of the Senate Health Committee could open a pipeline for the grand jury investigations of pharmaceutical marketing to feed into the Washington political debate.
Senate Transition Puts Kennedy Atop Health: Rx Marketing In Spotlight?
The return of Sen. Kennedy (D-Mass.) to the chairmanship of the Senate Health Committee could open a pipeline for the grand jury investigations of pharmaceutical marketing to feed into the Washington political debate.
FDA Dermatology Cmte. Chair Drake Among Pool Of Commissioner Names
FDA Dermatologic & Ophthalmic Drugs Advisory Committee Chair Lynn Annette Drake, MD, is one of more than a dozen names on lists prepared by D.C. trade associations and Congressional staffs as potential FDA commissioner nominees.